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Background: Physical disability in multiple sclerosis (MS) is frequently characterized by impaired ambulation.
Although walking tests have been successfully employed to assess walking ability in MS patients, data analytic
procedures have predominantly relied on result-oriented parameters (e.g. total distance covered during a given
amount of time), whereas process-oriented, dynamic walking patterns have mostly been ignored. This is striking,
since healthy individuals have been observed to display a stereotypical U-shaped pattern of walking speed during
timed walking, characterized by relatively high speed during the initial phase, subsequent slowing and final
acceleration. Objective of the current study was to test the utility of the 6 min Walk (6MW) and the 12 min Walk
(12MW) for revealing putatively abnormal temporal dynamic features of walking in MS.
Methods: A group of 37 MS patients was divided into subgroups with regard to their level of disability analyzed
with the Expanded Disability Status Scale (EDSS; Mild MS Group, n = 20, EDSS 0 – 3.5; Moderate MS Group, n = 17,
EDSS 4 – 5). Subsequently, both groups were compared to age-matched healthy controls (n = 25) on both tests
with regard to result-oriented characteristics (mean walking speed), as well as dynamic features (mean decline in
walking speed, degree of observed U-shape).
Results: Both MS groups showed a significantly lower mean walking speed than healthy controls, independent of
test duration. Compared to controls, the Moderate MS Group also slowed down more rapidly throughout both
tests. The same pronounced decline in walking speed was observed for the Mild MS Group in case of the 12MW.
Additionally, for both MS groups an attenuated U-shaped velocity pattern was observed relative to controls in the
6MW. Patients' subjective fatigue scores were more strongly correlated with the decline in walking speed than with
the common parameter of mean walking speed in the 6MW.
Conclusions: MS patients display abnormal dynamics in their walking patterns. A pronounced linear decline in
walking speed can be identified with the 12MW even in MS patients with seemingly mild disability. Similarly, the
6MW can be used to assess an abnormal walking profile. Particularly the linear decline in walking speed on this test
shows a more robust association with subjective fatigue than mean walking speed. Dynamic walking parameters
may hence represent valuable clinical features, serving as surrogate measures of motor fatigue. Future studies are
needed to verify their prognostic value.
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A wide range of tests is available to measure walking
performance in patients suffering from Multiple Sclerosis
(MS; see Kieseier et al. [1] and Bethoux et al. [2] for recent
reviews). Among the most widely used tests are the timed
25 Foot Walk, which measures the time a patient requires
to cover a distance of 25 feet at maximum speed, and the
6 min Walk (6MW), which measures the total distance a
patient is able to cover walking as fast as possible for six
minutes. Particularly the 6MW is commonly administered
and has been shown to display external validity, as per-
formance on this test is associated with balance confi-
dence and stair-climbing ability [3].
The application of the 6MW has consistently revealed
that MS patients may display considerable walking deficits.
Further, abnormal physiologic responses during walking
performance were reported. Savci et al. [4] for example
observed a significantly lower mean walking speed during
the 6MW in MS patients (n = 30, score on the expanded
disability status scale [5] EDSS = 1.5 – 6.0) compared to
controls (n = 30). The same pattern was observed by
Chetta et al. [6], who additionally reported reduced cardi-
orespiratory fitness, i.e. decreased oxygen pulse and ineffi-
cient ventilation, as reflected in an impaired breathing
pattern in MS patients (n = 11, EDSS = 1 – 3.5) compared
to controls (n = 10). These differences were observed des-
pite normal cardiopulmonary function at rest.
According to Motl et al. [7], even mildly disabled MS
patients may differ significantly from healthy controls in
their mean walking speed on the 6MW. Besides differences
in speed, a differential pattern of oxygen consumption
between the first and the second half of the test was
observed [8]. The authors concluded that different
metabolic systems may be relevant for performance
during the first and the second half of the 6MW.
Findings reported by Motl et al. [8] are particularly inter-
esting since parameters which are commonly derived from
walking tests (e.g. mean walking speed or total distance
covered) are not suitable to examine walking characteris-
tics which may vary during the test. In very few studies, an
attempt was made to examine dynamic walking features,
such as the progression of walking speed throughout the
test duration. In an early study, Schwid et al. [9] reported a
significantly lower median walking speed in MS patients
measured over a distance of 500 meters. MS patients how-
ever did not only walk slower, but also showed a consider-
able decrease in walking speed towards the end of the test,
whereas controls accelerated. Goldman et al. [10] exam-
ined velocity profiles of MS patients during the 6MW.
Results revealed that MS patients differed from healthy
controls in both, the mean walking speed as well as the
course of walking speed across the six-minute time span.
In case of the control group, a U-shaped velocity profile
was observed, with relatively high walking speed at thebeginning of the walk, subsequent slowing and acceleration
towards the end of the test. In contrast, in MS patients
the acceleration toward the end of the test was attenu-
ated [10]. The U-shaped pacing profile has previously
been described as a common phenomenon in healthy
participants, warranted that the duration of the per-
formed activity is sufficiently long [11]. Hence, the
examination of dynamic characteristics, such as the
change in walking speed at different stages of the test
may provide further, clinically relevant information.
Findings on dynamic walking patterns are also of rele-
vance for the ongoing discourse, whether walking tests
could be shortened to provide economically optimized
assessment tools for ambulation in MS. Gijbels et al.
[12,13] have suggested that an abbreviated version of 2
min duration may suffice to provide an estimate of walk-
ing ability. In their study, the authors reported a decline in
walking speed during the first three minutes and constant
pacing during the consecutive three minutes of the 6MW
in a sample of 40 MS patients (EDSS 1.5 – 6.5) [12].
Moreover a separately conducted 2MW showed the same
decline in mean walking speed per minute. Nevertheless,
findings by Schwid et al. [9], Goldman et al. [10] as well as
Motl et al. [8] are not necessarily consistent with this sug-
gestion and imply that shortening of the 6MW might re-
sult in the loss of potentially important information of
clinical relevance.
In this context, a further exploration of dynamic walk-
ing features in MS seems warranted. Even though the
observation of a specifically impaired walking profile
may be promising for future clinical applications, so far
only Goldman et al. [10] have provided information on
walking dynamics. The purpose of the current study was
to address this issue and to examine the walking dynam-
ics of MS patients more rigorously. In particular, the
intention was to replicate results by Goldman et al. [10]
and to apply further data analyses for a comparison of
walking profiles of MS patients and healthy participants.
Based on the suggestion that the duration of walking
needs to be sufficiently long to yield a U-shaped pacing
profile, in the current study, we examined whether the
6MW, as well as a 12 min Walk (12MW) would reveal
distinct dynamics in walking behaviour of MS patients
relative to healthy controls. We further collected self-
report data with regard to somatic fatigue, in order to
verify whether putatively abnormal walking dynamics
were related to patient's subjective constraints.
Methods
A group of 37 MS patients was recruited from the Depart-
ment of Neurology, Klinikum Bayreuth GmbH, Germany.
The comparison group consisted of 25 age-matched healthy
participants. Details regarding demographics and clinical
characteristics of the sample are displayed in Table 1. All
Burschka et al. BMC Neurology 2012, 12:161 Page 3 of 8
http://www.biomedcentral.com/1471-2377/12/161participants provided written informed consent prior to
study entry and the study was approved by the ethics com-
mittee of the Bavarian Medical Association, Germany. Infor-
mation about clinical characteristics was extracted from
patients’ files held by the Department of Neurology. Walking
tests (6MW, 12MW) were administered by a single, highly
trained clinical examiner during one or two patient visits.
Patients completed the two walking tests in randomized
order, with at least 3 hours between the assessments. The
administration of the 6MW followed standard protocol
[14], with modifications suggested by Goldman et al.
[10]. For six minutes, participants walked back and forth a
distance of 20m, which was divided into 1m segments
marked on a wall. Distance covered during each minute
was assessed visually, based on the marked segments, by
an examiner equipped with a stop-watch. The examiner
was seated ten meters away from the midpoint of the walk-
ing distance and recorded the distance covered during each
minute. This setting was chosen over other methods, such
as accompanying the patient with a precise wheel, in order
to minimize a putatively confounding influence of theTable 1 Demographics, clinical information and health behav
MS Patients (n = 37)
Demographics
Age M(SD) 39.7 (12.8)
Female sex, n (%) 28 (75.6)
Health Behavior
Tobacco users, n (%) 14 (37.8)
Body Mass Index, M(SD) 22.7 (5.7)
Physical activity/week, n (%)
< 1x 10 (27.0)
1-2x 20 (54.1)
> 3x 7 (18.9)
Clinical Information
MS course, n (%)
Relapsing-remitting 26 (70.3)
Secondary progressive 8 (21.6)
Clinically isolated syndrome 3 (8.1)
MS Duration in years, M(SD)
Relapsing-remitting 6.4 (7.8)
Secondary progressive 6.4 (5.6)
EDSS median (range)
Mild MS 2 0 – 3.5
Moderate MS 4 4 – 5




b chi square test.setting on the participants’ walking behaviour. The 12MW
followed the same procedure, with the only difference that
the walking duration was twice as long. Additionally, the
Wuerzburger Fatigue Inventory for Multiple Sclerosis
(WEIMuS) was implemented prior to the first test as a
measure of subjective somatic fatigue [15].
In order to gain information about walking dynamics
with regard to MS-related disability, in a first step, patients
were sorted into subgroups displaying moderate and mild
disability. Group membership was determined based on the
EDSS (Moderate MS Group, EDSS > 3.5, n = 18; Mild MS
Group, EDSS < 4, n = 19). Scores below 4 refer to patients
who are fully ambulatory, while scores between 4 and 5.5
refer with walking impairment who are able to walk at least
100m without assistive devices [5].
Statistical analyses were performed with SPSS 20.0.
Differences in mean walking speed (meters/minute)
between MS patients and controls were assessed by a two-
way repeated measures ANOVA with the within-subjects
factor Test (6MW, 12MW) and the between-subjects fac-
tor Group (Mild MS, Moderate MS, Controls). Given aior
Controls (n = 25) statistic p-value
38.4 (11.9) 0.40a 0.69
18 (72.0) 0.11b 0.75
6 (24.0) 1.31b 0.25
23.8 (3.8) - 0.89a 0.41
7 (28.0)
12 (48.0) 0.30b 0.86
6 (24.0)
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a detectable effects size of f = 0.2, when relying on levels of
α = 0.05 and β = 0.8. The omnibus test was followed up by
two-sided t-tests with Bonferroni-corrected p-values to
avoid Type I error inflation.
More importantly, linear and quadratic trends in the
walking profiles were examined. In the data obtained in
the current study, a quadratic trend reflected the degree
to which the walking profile of each group approximated
a U-shaped pattern. The linear trend served as an esti-
mate of deceleration. The analyses explored, whether the
distance covered during each test minute varied through-
out the respective test, and whether putative linear and
quadratic trends differed between groups. To this end,
a repeated measures ANOVA with the within-subjects
factor Minute (6MW: 1-6; 12MW: 1-12) and the
between-subjects factor Group (Mild MS, Moderate
MS, Controls) was conducted separately for each test.a
In an additional analysis, Pearson correlations were
used to test for an association between subjective som-
atic fatigue (WEIMuS-Score) and walking parameters.
Results
Mean walking speed
Healthy participants walked significantly faster than both
groups of MS patients (see Table 2 for the total distance
walked). In particular, the examined groups differed in
their average walking speed, as revealed by a highly sig-
nificant main effect of Group [F(2,59) = 61.65, p < 0.001].
The ANOVA further showed that overall walking speed
was affected by walking duration, as indicated by a sig-
nificant main effect of Test [F(1,59) = 55.18, p < 0.001].
The Group by Test interaction also reached significance
[F(2,59) = 3.34, p < 0.05].
Post-hoc comparisons indicated that the main effect of
Group was due to significant differences in walking
speed between controls and the Moderate MS Group as
well as significant differences between controls and the
Mild MS group in both tests. The pattern of group dif-
ferences was consistent across tests, albeit more pro-
nounced in the 6MW (Table 3).
Linear trend component: decline in walking speed
In the 6MW, patients continuously slowed down through-
out the test, and this decline in speed was significantly pro-
nounced relative to healthy controls (Figure 1). In particular,
the duration of walking affected the walking speed, asTable 2 Total distance covered during the 6MW and the 12M
Controls (n = 25)
Total distance covered in meters M SD
6MW 681 88
12MW 1305 157revealed by a significant main effect of Minute
[F(5,295) = 57.76, p < 0.001], with a highly significant
linear trend [F(1,59) = 64.26, p < 0.001]. The linear
trend, however, was differentially expressed across
groups, as revealed by a highly significant Minute by
Group interaction [F(2,59) = 7.00, p < 0.01]. Post hoc
comparisons indicated a significantly pronounced de-
cline of walking speed in the Moderate MS Group, rela-
tive to controls whereas the difference between
controls and the Mild MS Group was not significant
(Table 3).
The same pattern of a stronger decline in walking speed
in patients, relative to controls, was observed in case of the
12MW (Figure 1). In this case, analyses revealed a signifi-
cant main effect of Minute [F(11,649) = 35.13, p < 0.001],
with a significant linear trend [F(1,59) = 46.08, p < 0.001],
which was differentially expressed across groups [F(2,59) =
21.54, p < 0.001]. For both groups of patients, the decline in
speed was significantly pronounced, relative to healthy con-
trols (Table 3).
Quadratic trend component: degree of observed U-shape
Overall, participants' performance approximated a U-
shaped velocity profile in the 6MW. However, the U-shape
was significantly attenuated in MS patients, relative to
healthy controls. In particular, there was a highly significant
quadratic trend [F(1,59) = 129.73, p < 0.001] which was dif-
ferentially expressed across groups, as indicated by a highly
significant Minute by Group interaction [F(2,59) = 10.82,
p < 0.001]. As displayed in Table 3, further testing showed
that the quadratic trend was significantly attenuated in
both, Mild MS and Moderate MS groups, relative to
healthy participants.
The general pacing profile also approximated a U-shaped
pattern in the 12MW. In this case the observed U-shape
did not vary across groups, and the overall significant
quadratic trend [F(1,59) = 89.82, p < 0.001] was not charac-
terized by a significant Minute by Group interaction
[F(2,59) = 1.90, p > 0.05].
Obtained walking dynamics and subjective somatic
fatigue
Within the MS group, the self-report parameter of somatic
fatigue [15] showed significant correlations with mean
walking speed [6MW: r = -0.38; 12MW: r = -0.36, p < 0.05,
respectively] and highly significant correlations with the lin-
ear decline in walking speed [6MW: r = -0.63; 12MW:
r = -0.56, p < 0.001, respectively] in both tests.W
Mild MS (n = 19) Severe MS (n = 18)
M SD M SD
586 73 422 69
1151 148 792 134
Table 3 Mean walking speed, derived linear and quadratic trend components of walking dynamics
Controls (n = 25) Mild MS (n = 19) Statistic Severe MS (n = 18) Statistic
M SD M SD T p M SD T p
6MW
Mean speed m/min 113.44 14.59 97.71 12.20 3.80 0.000*** 70.41 11.49 10.40 0.000***
Linear trend -0.42 0.55 -0.37 0.35 -0.33 0.745 -1.00 0.78 2.87 0.006**
Quadratic trend 0.52 0.22 0.32 0.23 2.90 0.006** 0.19 0.26 4.50 0.000***
12MW
Mean speed m/min 108.75 13.10 12.37 12.37 3.31 0.002** 66.01 11.16 11.21 0.000***
Linear trend -0.00 0.25 -0.22 0.33 2.52 0.016* -0.73 0.51 5.63 0.000***
Quadratic trend 0.05 0.04 0.05 0.03 0.02 0.983 0.03 0.03 1.68 0.100
Comparisons performed between groups of Mild MS patients and healthy controls, as well as Severe MS Patients and healthy controls.
*p-value < 0.05 ** p-value < 0.01 *** p-value < 0.001.
Figure 1 Velocity profiles of members of the Mild MS,
Moderate MS and healthy control group on the 6 min Walking
Test (6MW, top) and the 12 min Walking Test (12MW, bottom).
Distance covered is displayed in meters.
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linear decline and somatic fatigue was significantly stron-
ger than the association between mean walking speed and
somatic fatigue, Steiger's Z-test was used. This revealed
that self-reported somatic fatigue was more strongly asso-
ciated with the decline in speed than with mean walking
speed in the 6MW [6MW: Z = 1.98, p < 0.05]. In the
12MW, the difference between the strength of correlations
of self-reported somatic fatigue and walking behavior
(mean walking speed, linear decline in walking speed) did
not reach statistical significance [12MW: Z = 1.50, p > 0.05;
two-tailed]. For the control group no significant correla-
tions were obtained (all p-values > 0.05). An exploratory
analysis further revealed that there were no significant cor-
relations between the self-report parameters and observed
quadratic trends (all p-values > 0.05).Discussion
Walking tests are frequently used to examine ambula-
tion in MS patients [1,2]. However, analytic proce-
dures applied to data derived from walking tests, with
few exceptions [8-10], remained relatively superficial,
leaving temporal walking dynamics almost unex-
plored. We examined three characteristics of walking
behavior in two walking tests, comparing MS patients
of mild and moderate disability to healthy controls.
Besides the common parameter of mean walking
speed, velocity profiles included the linear and the
quadratic trend of walking speed during a 6 min
Walk (6MW) and a 12 Minute Walk (12MW). The
linear trend reflected a measure of deceleration over
time, while the quadratic trend estimated the degree
to which the walking profile of each group approxi-
mated a U-shape. With this analysis, we intended to
confirm and extend observations made by Goldman
et al. [10] who reported distinct patterns in the walk-
ing behavior of MS patients and healthy controls dur-
ing the 6MW.
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Firstly, our results are consistent with findings of Goldman
et al. [10], confirming that MS patients walked slower
than controls in both tests. In our sample, both,
mildly and moderately disabled MS patients displayed
attenuated walking speed, relative to controls. As MS
commonly affects ambulation, this observation is in
line with the extant literature [4,6,9]. The fact that
even MS patients with mild disability (Mild MS group)
differed significantly from controls in their mean
walking speed is noteworthy. This finding hints at an
early influence of MS on walking ability in the examined
sample and supports previous reports [7,10,16-18].
Linear trend in walking speed: mean decline
More importantly, results of the current study indicate
that differences in walking behavior between MS patients
and controls do not only manifest in mean walking speed,
but also in altered dynamic walking parameters.
MS patients with moderate disability slowed down more
rapidly than controls on both tests. Complementary,
MS patients with mild disability displayed a pro-
nounced deceleration in case of the 12MW. These
novel findings indicate that continuous deceleration, as
reflected by the linear trend in walking speed, repre-
sents an additional, clinically relevant feature of
impaired ambulation in MS patients. While for patients
with moderate disability, the 6MW represents a test
which is sufficient to detect this clinical feature, for
patients with mild disability, a considerably longer
walking duration, as in the 12MW, seems necessary.
The linear decline in walking speed was significantly
pronounced in patients, relative to healthy controls,
which indicates that deceleration represents a clinically
relevant feature. However, the current study provides
further original information on the utility of this parameter.
In particular, the linear decline in walking speed was
highly correlated with subjective somatic fatigue. This
provides convergent evidence, indicating that the pro-
nounced deceleration also represents a good estimate
of patients' subjective constraints. It is especially note-
worthy that linear deceleration showed highly signifi-
cant correlations with subjective somatic fatigue (all
p-values < 0.001), whereas the commonly used param-
eter of mean walking speed showed only minor associa-
tions with somatic fatigue (all p-values < 0.05). Since
these correlations differed significantly from each other
in the 6MWb, linear deceleration may in fact represent
a more suitable parameter to assess somatic fatigue
than mean walking speed. This appears plausible, since
the dynamic notion of deceleration seems more congruent
with the phenomenon of motor fatigue, than the mean
walking speed. In sum, our results indicate that deceler-
ation reflects a potentially useful parameter, which issuitable for the assessment of somatic fatigue. As such, our
findings provide strong support for the notion of Goldman
et al. [10], who suggested to interpret the decline in walking
speed as an indicator of fatigue in MS patients.
Quadratic trend in walking speed: degree of observed u-
shape
We also found a U-shaped velocity profile (quadratic trend)
across both tests in all groups combined. A U-shaped
pacing strategy is a known phenomenon in healthy indivi-
duals [11]. As hypothesized, the degree of the U-shape was
attenuated in MS patients, relative to controls in the 6MW.
Even MS patients with mild disability showed an attenuated
U-shape relative to controls on this test. This indicates, that
the U-shaped profile can also be regarded as a clinically
relevant parameter in MS. However, compared to the
parameter of linear deceleration, it does not appear to be as
informative, since no association with subjective fatigue
was obtained and differences in the U-shaped pattern
between the studied groups were not found in the 12MW.
Nevertheless, since studies in which this dynamic charac-
teristic is utilized are sparse, the current work provides ori-
ginal results on a new, promising clinical feature, worthy to
be explored in more detail in the future.
Which walking test to use?
Recently, it has been suggested that a brief test including
only two minutes of walking (2MW) represents a suffi-
cient measure of walking ability in MS patients [12]. This
suggestion was based on a high correlation between the dis-
tances covered during the 2MW and the 6MW [12]. Given
this correlation, such a suggestion appears feasible when
considering the total distance walked. Nevertheless, results
of the current study suggest that the choice of which test to
use depends on the walking parameter which is supposed
to be assessed. For practical reasons, the parameter of mean
walking speed, or total distance covered during a given
amount of time, has received most attention in research on
ambulation in MS. The current study provides novel
findings, according to which further parameters can be
derived from standard walking tests, which are of high
clinical relevance. Particularly the linear trend, as a measure
of deceleration, appears to be promising as an estimate of
impaired walking ability, since it can be easily derived from
a standard walking test. However, since it is not necessarily
warranted to derive this measure from a test of only two
minutes duration, the current findings do not provide
direct support for the suggestion to drastically shorten
common tests. In line with this conclusion, Motl et al. [8]
have reported that a further putatively relevant parameter,
i.e. oxygen consumption, does not reach a steady state
within the first two minutes of walking, but remains un-
altered only after the third minute. The latter authors sug-
gest that the 2MW functions as a measure of primarily
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performance. Based on our results obtained in case of the
6MW, particularly this test appears to be a feasible measure
to capture both, well established parameters, such as the
total distance walked, as well as parameters which vary
during the walking test. Our findings indicate that an ab-
breviation of the test duration might result in the loss of
potentially important information on dynamic walking be-
havior, which to date has remained relatively unexplored.
Dynamic parameters could serve as a means to increase
sensitivity of walking tests to abnormal walking behavior
within MS patients.
Limitations and future directions
In an innovative study Phan-Ba et al. [18] have recently
utilized the combination of a timed 500 meter walk
(T500MW) and a timed 25 foot walk (T25FW) to assess
deceleration in MS. The authors quantified deceleration
by computing a combined deceleration index, consisting
of the ratio of walking speed during the last 100 meters
of the T500MW and throughout the T25FW. The
authors suggest that such a ratio may be particularly
useful to assess ambulation impairment during late
stages of MS. Hence, future studies which distinguish
between MS subtypes and which explore methodological
means to derive further parameters of dynamic walking
characteristics may be warranted.
While the current results are in accord with this as-
sumption, they are to be interpreted in the context of
few limitations. In particular, it should be noted that the
quantification of walking behavior was achieved through
visual inspection by an examiner equipped with a stop-
watch. This setting was chosen over the one in which a
patient is accompanied by an examiner equipped with a
precise measurement wheel, to reduce a putatively con-
founding influence of the setting on walking perform-
ance. It is also the approach commonly used in the
clinic where the work was carried out. On the other
hand, it can be argued that visual inspection may also
have an effect on walking performance, and the use of a
measurement wheel would have provided a technically
more precise measure of walking speed. Hence, the
examiner could either have accompanied the patient
with the measurement wheel, or the patient could have
been equipped with the measurement wheel. Either
option may represent a useful alternative to the
method implemented in the current study. This fact
may be regarded as a caveat to the interpretation of
the current results.
Finally, it needs to be noted that the walking para-
meters explored in the current study imply an alter-
ation of the common nomenclature used in the
literature. Performance on walking tests is usually re-
ferred to in terms of the total distance covered during agiven amount of time. For the use of walking behaviour
which changes throughout the test (e.g. deceleration) as
a test parameter, a nomenclature involving walking
speed appeared more feasible. Nevertheless, when it
comes to the interpretation of the current results, it
needs to be considered that this nomenclature does not
match the one of the extant literature on common
walking parameters.
Conclusions
Our findings highlight the necessity of thoroughly consid-
ering the diagnostic goal of a walking test. It is known that
the parameter of mean walking speed can be reliably
derived from relatively short tests, e.g. the 2MW [12].
However, this parameter might oversimplify the concept
of walking impairment, and only tests of longer duration,
such as the 6MW, can be used to derive dynamic para-
meters, which are potentially more informative. As an
augmentation to the current standard of measures of
walking ability, we contribute a method of quantifying dy-
namic walking patterns, such as the linear decline in walk-
ing speed (linear trend). The linear trend could serve as a
surrogate parameter of motor fatigue. It might be better
suited than the total distance walked because of its signifi-
cantly higher correlation with patients' subjective somatic
fatigue in the 6MW. Our results support the choice of a
longer test duration (12 min) only for MS patients with
mild disability (estimated by an EDSS score of less than 4).
A shorter test duration (6 min) appears to be sufficient to
examine dynamic walking characteristics in MS patients
with potentially more moderate deficits (estimated by an
EDSS score greater than 3.5). The early registration of
changes in walking ability is a key to therapy aimed at
minimizing the impairment of mobility. We recommend
further research to more thoroughly explore abnormal dy-
namic walking features in MS, and to establish normative
data for these parameters.
Endnotes
a The linear trend (first order polynomial trend com-
ponent) describes the mean slope of the velocity pro-
file [8]. An example of the calculation: D1, D2, . . . Dn
reflect the distance covered during the first, second,
. . ., n-th minute of the walking test. Calculation of the
linear trend in the 6MW can be achieved with this for-
mula: LinearTrend6MW = ((-5*D1) + (-3*D2) + (-1*D3) +
(1*D4) + (3*D5) + (5*D6))/70 Different formulas were uti-
lized for the 12MW and the quadratic trend [19].
b The fact that the difference between the correlation
of linear trend of walking speed and subjective somatic
fatigue and the correlation of mean walking speed and
subjective somatic fatigue reached statistical signifi-
cance only in the 6MW but not in the 12MW may be a
power issue.
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